Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Congress Maintains Prostate Cancer Research Funding at Historic $110M



Ilana Ostrin

Washington, D.C. – In a time when politicians are often pitted against one another, members of the U.S. House of Representatives on both sides of the aisles have once again come together to save men’s lives. Earlier today, the House voted to maintain the highest ever funding for the Prostate Cancer Research Program (PCRP), at a historic level of $110M. FY20 was the first year $110M was granted to the program, which helps seed more research projects and innovative breakthroughs for the nation’s more than three million prostate cancer patients.

ZERO is grateful for the leadership of Rep. Sanford Bishop (D-GA) and Rep. Peter King (R-NY), along with DoD Subcommittee Chairman Peter Visclosky (D-IN) and Ranking Member Ken Calvert (R-CA) in this effort. More than 150 Representatives have signed-on in support of maintaining PCRP funding at its current levels.

Additionally, ZERO applauds the hundreds of fierce advocates and ZERO Champions from around the country who have attended the ZERO Prostate Cancer Summit, an annual advocacy and education event on Capitol Hill that brings awareness to the critical need for more prostate cancer research funding. These individuals, plus all those who have called and written to their elected officials in support of prostate cancer research, have made a difference through their concerted efforts. 

Since its founding, the work of the PCRP has led to four market-ready advanced prostate cancer treatments (XGEVAⓇ, ZYTIGAⓇ, XTANDIⓇ, and ERLEADAⓇ) and one diagnostic test (Oncotype DX AR-V7 Test).

“This is an awesome victory for patients and their families,” said ZERO CEO, Jamie Bearse. “By keeping the PCRP funded at its highest-ever level, patients in the fight of their lives have one more reason to hope. Breakthroughs from the PCRP have proven to lead to tomorrow’s life-saving treatments and diagnostic tools.”

Caesar Blevins, an advanced prostate cancer patient in Kansas City, travels to the nation’s capital every year for the ZERO Prostate Cancer Summit, where he shares his personal and touching cancer story with his elected officials in Congress. “I will keep coming back as long as I need to in order to help save the lives of patients like me,” said Blevins. “I’m grateful to all the Congressional leaders who worked hard to ensure that patients like me have more hope and support thanks to the potential of new treatment possibilities.”

New treatment options for advanced prostate cancer patients are critical to survival. Prostate cancer — which kills a man every 16 minutes —  has only about a 30 percent survival rate once it reaches advanced stages.

This appropriation is expected to move to the Senate in the near future. To stay tuned to upcoming advocacy alerts on this important initiative, visit zerocancer.org.

About ZERO — The End of Prostate Cancer
ZERO — The End of Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer and help all who are impacted. ZERO advances research, provides support, and creates solutions to achieve health equity to meet the most critical needs of our community. From early detection to survivorship, ZERO is the premier resource for prostate cancer patients and their families to access comprehensive support, make meaningful connections, and take action to save lives. Our dedicated national and chapter staff is joined with a growing team of passionate volunteer champions to increase advocacy, awareness, and community engagement to ZERO out prostate cancer. ZERO is recognized with four out of four stars by Charity Navigator and accredited by the Better Business Bureau. ZERO spends more on programs than any other prostate cancer charity, dedicating 85 cents of every dollar to support, education, and research.